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Background
Recent studies of antibodies in human plasma from HIV-
1-infected and immunized individuals have revealed an
important role for the V1/V2 region of gp120 in an anti-
viral response, and recent evidence that protection in the
RV144 vaccine trial correlated with the presence of V1/
V2-specific antibodies suggests that the V1V2 region is an
important target for candidate HIV-1 vaccines. However,
the function of V1V2-specific antibodies is not well under-
stood. In this study we present data about the develop-
ment, subtype specificity, and neutralization activity of
such antibodies present in plasma from several hundred
infected North American and African subjects.
Methods
Human plasma from infected individuals were screened
for neutralization activity versus a panel of subtype B,
subtype C, and other Tier 2 pseudoviruses, and were
titrated for binding activity against the consensus subtype
B, C and A/E V1/V2 fusion glycoproteins, expressed via
fusion to a fragment of the MuLV gp70 sequence. This
system expresses V1/V2 domains in their native glycosy-
lated and conformational forms. V1V2-specific antibodies
were isolated from selected plasma by immunoaffinity
chromatography on gp70-V1/V2 antigen columns, and
characterized for neutralizing activity against various
HIV-1 pseudoviruses.
Results
Most (>80%) of the HIV-1 infected subjects possessed
robust levels of V1/V2 binding activity versus the three
antigens. Interestingly, the development of V1/V2-reac-
tive antibodies tracked with the development of autolo-
gous neutralizing antibodies in several subjects infected
with subtype C viruses. Immunoaffinity-purified V1/V2-
specific antibodies from selected broadly neutralizing
plasma samples also possessed broad neutralization
activities, with IC50s generally in the 1-20 μg/ml range.
Conclusion
Highly cross-reactive V1V2-specific antibodies were pre-
sent in almost all broadly neutralizing human plasmas at
large concentrations, and frequently possessed modest
neutralizing activities against a range of isolates, including
tier 2 viruses. Additional information about the nature of
these antibodies and their target epitopes would help elu-
cidate their potential roles in protection against infection.
Author details
1PHRI/UMDNJ, Newark, NJ, USA. 2Emory Vaccine Center, Atlanta, GA, USA.
3Montefiore Medical Center, Bronx, NY, USA.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P92
Cite this article as: Krachmarov et al.: Characterization of V1/V2-specific
antibodies present in broadly neutralizing plasma isolated from HIV-1
infected individuals. Retrovirology 2012 9(Suppl 2):P92.
1PHRI/UMDNJ, Newark, NJ, USA
Full list of author information is available at the end of the article
Krachmarov et al. Retrovirology 2012, 9(Suppl 2):P92
http://www.retrovirology.com/content/9/S2/P92
© 2012 Krachmarov et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
